AST-VRE Screen
HOME      CONTACT US      EQA PROGRAMS      RESULTS     CRITIQUES     SITE MAP
Click on the drop-down button for links to critiques from other sources

Contact us to obtain critiques older than 5 years.
Scroll down to find Critique number of older challenges and a brief description.
Some older archived critiques are included in this list, but CMPT advises visitors to also consult recent literature.
Disclaimer: Please consult most recent CLSI guidelines and SOPs for your laboratory. See CLSI information page.
YEAR CRITIQUE NUMBER SUMMARY See revised ID Table 7 (Jan 2007)
2006 M063-4 VRE positive, Enterococcus faecium. a borderline resistant vanB isolate of E. faecium. It was peculiar in having a vancomycin MIC of approximately 12 – 16 mg/L and so was considered as vancomycin intermediate. From original clinical screening specimens it also grew slowly. Notification of Infection Control required.
2005 M051-5 Enterococcus gallinarum is not a true VRE - does not require strict infection control measures. Antimicrobial Susceptibility Testing: Reporting ampicillin/amoxicillin /(penicillin) and high-level gentamicin as sensitive and vancomycin as either intermediate or resistant each scored a grade of 4.
2003 M034-2 Blood culture isolate: Not a VRE, but a high-level gentamicin resistant strain of Enterococcus faecalis.
2002 M023-2 Rectal swab for VRE screen VRE positive -See CEQA - AGAR (Canadian External Quality Assessment Advisory Group on Antibiotic Resistance) Guidelines, titled ‘Revised Guidelines for the Testing and Reporting of Antimicrobial Susceptibilities of Vancomycin Resistant Enterococci’. These guidelines define VRE, note the specimens with the highest likelihood of containing VRE and include methods for identification and interpretation.